The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Exclusion Criteria

• •Repeatedly symptomatic hypotension, systolic blood pressure of less than 90 mmHg and diastolic blood pressure of less than 60 mmHg, which cannot tolerate the RASS inhibitors therapy
• •Patients who have significant fluid overload and did not reach dry weight stably
• •Patients with acute myocardial infarction or implantation of intracoronary stents, coronary artery bypass grafting (CABG) and pacemaker within three months
• •Patients with special type of heart disease, including cardiac amyloidosis, congential heart disease and pericardial disease
• •Patients with malignant hypertension and hypertensive emergencies that can not be controlled
• •Patients with significant impaired liver function
• •Patients with repeatedly or server infection
• •Allergic to the trial drugs
• •Unacceptable side effects during receipt of RASS inhibitors
• •Pregnancy
• •Patients who are unable to provide informed consent